Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Lipella Pharmaceuticals Inc (LIPO)

Lipella Pharmaceuticals Inc (LIPO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,179
  • Shares Outstanding, K 1,209
  • Annual Sales, $ 450 K
  • Annual Income, $ -4,620 K
  • EBIT $ -4 M
  • EBITDA $ -4 M
  • 60-Month Beta 0.31
  • Price/Sales 6.50
  • Price/Cash Flow N/A
  • Price/Book 2.01

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.21 +19.00%
on 11/15/24
3.84 -31.48%
on 10/23/24
-1.18 (-30.93%)
since 10/22/24
3-Month
2.21 +19.00%
on 11/15/24
4.56 -42.32%
on 08/23/24
-0.73 (-21.71%)
since 08/22/24
52-Week
2.21 +19.00%
on 11/15/24
12.00 -78.08%
on 07/29/24
-6.17 (-70.11%)
since 11/22/23

Most Recent Stories

More News
Lipella Pharmaceuticals Completes Dosing for First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus

Lipella Pharmaceuticals completes initial dosing in Phase 2a trial of LP-310 for Oral Lichen Planus, showing promising results.Quiver AI SummaryLipella Pharmaceuticals Inc. has announced the completion...

LIPO : 2.63 (+8.68%)
Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group

LIPO : 2.63 (+8.68%)
Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform

LIPO : 2.63 (+8.68%)
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split

LIPO : 2.63 (+8.68%)
Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference

LIPO : 2.63 (+8.68%)
Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform

LIPO : 2.63 (+8.68%)
Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit

LIPO : 2.63 (+8.68%)
Lipella Pharmaceuticals Advances With Multiple Near-Term Catalysts and Strategic Focus on Rare Diseases

Lipella Pharmaceuticals is a clinical-stage biotechnology company that focuses on developing and commercializing treatments for serious diseases with significant unmet needs.

LIPO : 2.63 (+8.68%)
Rising Number of Studies to Develop Novel Therapies For Pancreatic Ductal Adenocarcinoma (PDAC) Intensely Increasing

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:LIPO) EQNX::TICKER_END

ONCY : 0.9541 (-2.64%)
ONC.TO : 1.33 (-2.92%)
CRDF : 2.45 (-2.00%)
LLY : 748.01 (-0.25%)
ABBV : 176.95 (+3.04%)
LIPO : 2.63 (+8.68%)
Lipella Pharmaceuticals Enters Manufacturing Collaboration Agreement with Cook MyoSite

/PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company addressing serious diseases...

LIPO : 2.63 (+8.68%)

Business Summary

Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Lipella Pharmaceuticals Inc. is based in PITTSBURGH.

See More

Key Turning Points

3rd Resistance Point 3.03
2nd Resistance Point 2.86
1st Resistance Point 2.75
Last Price 2.63
1st Support Level 2.47
2nd Support Level 2.30
3rd Support Level 2.19

See More

52-Week High 12.00
Fibonacci 61.8% 8.26
Fibonacci 50% 7.11
Fibonacci 38.2% 5.95
Last Price 2.63
52-Week Low 2.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar